Performance of polymethyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicone membrane oxygenators

Objective: To review the performance of polymethyl pentene versus silicone oxygenators in terms of efficiency in priming and oxygenation, oxygenator resistance, requirements for coagulation proteins and consumption of blood products, for neonatal extracorporeal membrane oxygenation (ECMO) patients. Study design: Forty consecutive neonates were selected retrospectively pre- and post-introduction of the new polymethyl pentene (PMP) oxygenators. They formed two equal groups. After calculation of the sample size, data were collected from ELSO registry forms and patient records. Results were analysed using parametric and non-parametric tests. Results: Neonatal PMP (N-PMP) oxygenators were smaller, faster and easier to prime. They were less efficient than silicone oxygenators, especially in carbon dioxide elimination, and, therefore, required higher sweeps. The preservation of coagulation proteins was significantly better, but there was no reduction in the consumption of blood products, despite having less than half the surface area and significantly lower blood path resistance. Conclusion: Small PMP oxygenators (Medos Hilite 800 LT) provide adequate gas exchange and offer technical advantages in terms of more efficient priming, reduced haemodynamic resistance and better control and preservation of coagulation proteins than silicone oxygenators.

[1]  A. Sosnowski,et al.  Poly-Methyl Pentene Oxygenators Have Improved Gas Exchange Capability and Reduced Transfusion Requirements in Adult Extracorporeal Membrane Oxygenation , 2005, ASAIO journal.

[2]  G. Tangen,et al.  Heparin‐Coated Circuits (Duraflo II) With Reduced Versus Full Anticoagulation During Coronary Artery Bypass Surgery , 2003, Journal of cardiac surgery.

[3]  G. Peek,et al.  Early Experience with a Polymethyl Pentene Oxygenator for Adult Extracorporeal Life Support , 2002, ASAIO journal.

[4]  L. Menicanti,et al.  The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits. , 2002, Journal of cardiothoracic and vascular anesthesia.

[5]  T. Karlsson,et al.  Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  L. V. von Segesser,et al.  Impact of hollow-fiber membrane surface area on oxygenator performance: Dideco D903 Avant versus a prototype with larger surface area. , 2000, The journal of extra-corporeal technology.

[7]  G. Peek,et al.  The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. , 1999, ASAIO journal.

[8]  C. Hack,et al.  Specific complement inhibition with heparin-coated extracorporeal circuits. , 1996, The Annals of thoracic surgery.

[9]  P. Beckley,et al.  Comparison of the performance characteristics of three generations of membrane oxygenators: Univox®, Univox® Gold™ and SpiralGold™ , 1996 .

[10]  R. Colman,et al.  Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. , 1996, The Journal of thoracic and cardiovascular surgery.

[11]  L. Menicanti,et al.  Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction. , 1996, The Annals of thoracic surgery.

[12]  J. Maessen,et al.  Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. , 1995, The Journal of thoracic and cardiovascular surgery.

[13]  E. Fosse,et al.  High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. , 1995, The Annals of thoracic surgery.

[14]  D. Holt,et al.  Oxygenators for Extracorporeal Circulation , 1995 .

[15]  N. Hatori,et al.  Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. , 1994, Artificial Organs.

[16]  E. Fosse,et al.  Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.

[17]  B. Nilsson,et al.  Complement activation during cardiopulmonary bypass: effects of immobilized heparin. , 1994, The Annals of thoracic surgery.

[18]  M. Ziegler,et al.  The significant relationship between platelet count and haemorrhagic complications on ECMO , 1994, Perfusion.

[19]  W. Baumgartner,et al.  Heparin-coated bypass circuits reduce pulmonary injury. , 1993, The Annals of thoracic surgery.

[20]  W. van Oeveren,et al.  Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[21]  R. Bartlett,et al.  A heparin-coated circuit reduces complement activation and the release of leukocyte inflammatory mediators during extracorporeal circulation in a rabbit. , 2008, Artificial organs.

[22]  P. Venge,et al.  Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.

[23]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[24]  C. Wildevuur,et al.  Clinical experience with heparin-coated cardiopulmonary bypass circuits , 1991, Perfusion.

[25]  V. Videm,et al.  Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. , 1991, The Journal of thoracic and cardiovascular surgery.

[26]  M. R. Rolfs,et al.  Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits. , 1990, ASAIO transactions.

[27]  M L BRAMSON,et al.  A NEW DISPOSABLE MEMBRANE OXYGENATOR WITH INTEGRAL HEAT EXCHANGE. , 1965, The Journal of thoracic and cardiovascular surgery.